Ceesay Abraham 4

What Happened

• Ceesay Abraham, CEO of Rapport Therapeutics (RAPP), received a derivative award for 428,000 shares on Feb 2, 2026. The Form 4 reports the acquisition price as $0.00 and classifies the transaction as an award/grant (code A). The filing’s footnote states the shares underlying this option will vest and become exercisable in 48 equal monthly installments beginning January 1, 2026, subject to continued service.
• This was an award/acquisition (not a sale or immediate exercise); no immediate sale or cashless exercise was reported.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely).
• Reported amount: 428,000 shares (derivative award) at reported price $0.00.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnote: Vesting/exercisability occurs in 48 equal monthly installments following Jan 1, 2026, subject to continued service.
• Filing accession: 0001193125-26-037603 (SEC Form 4).

Context

• This is a derivative award (option-like) that vests over time; the filing notes vesting schedule but does not disclose any exercise price or immediate sale. Such awards are commonly used to align executive incentives with shareholder value; they do not by themselves indicate imminent buying or selling of stock.